Syqe begins marketing medical cannabis inhaler
The new inhaler, which allows doctors to prescribe precise dosages, has received Ministry of Health approval in Israel.
The company has raised $83 million to date from investors including Philip Morris and OurCrowd.
Syqe’s drug delivery technology includes complex respiration technique automation, electronic selective dosing and remote clinical monitoring and dose control, significantly expanding the applicability of this platform well beyond cannabis.
Syqe founder and CEO Perry Davidson said, “80% of cannabis patients inhale the plant. For too long, physicians who wish to treat these patients have been without the most basic clinical knowledge on dosing, efficacy and adverse events of cannabis. For 8 years Syqe has been developing proprietary technologies for the administration of raw plants, and through our clinical trials we were able to determine the recommended dosage of inhaled cannabis down to the microgram. This launch marks the beginning of a new chapter in pain treatment, one in which physicians can confidently prescribe precise dosages of cannabis, and patients can reap the rewards, effectively and responsibly.”
Published by Globes, Israel business news – en.globes.co.il – on June 20, 2019